GlassScriptPhysician profile
Raj Butani
NPI 1285695221
$7,164.95
in general payments reported to CMS, 2019-2025
37 companies · $925 in 2025
The $925 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $411 · 2021: $785 · 2022: $1,010 · 2023: $1,361 · 2024: $1,727 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,012.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,543.60 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Pfizer INC. | $868.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $527.09 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $465.70 | 2019-2024 | |
| Janssen Biotech, INC. | $377.17 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $362.61 | 2019-2025 | Eohilia, Entyvio |
| Boston Scientific Corporation | $352.51 | 2020-2025 | Apollo Esg Nxt System, Cre Pro |
| Celgene Corporation | $295.08 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $237.33 | 2024-2025 | Zenpep, Vowst |
| Genzyme Corporation | $205.35 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $198.33 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $126.33 | 2022 | |
| Intercept Pharmaceuticals, INC. | $125.02 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $124.10 | 2019-2024 | Dificid |
| Organon LLC | $123.51 | 2022-2024 | Hadlima |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $122.16 | 2025 | Iqirvo, Bylvay |
| E.R. Squibb & Sons, L.L.C. | $118.17 | 2021 | |
| Phathom Pharmaceuticals, INC. | $113.96 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $113.17 | 2021 | |
| Aries Pharmaceuticals, INC. | $108.42 | 2019 | |
| Amgen INC. | $75.33 | 2021-2022 | |
| Qol Medical, LLC | $69.71 | 2021-2025 | Sucraid |
| Cook Medical LLC | $64.07 | 2025 | Echotip Insight |
| Allergan, INC. | $64.00 | 2019 | |
| Lilly USA, LLC | $49.84 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $47.36 | 2019 | |
| Ucb, INC. | $45.94 | 2020-2021 | |
| Ardelyx, INC. | $44.26 | 2022-2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $41.79 | 2021-2022 | |
| Alfasigma USA, INC. | $32.43 | 2020 | |
| Recordati_rare_diseases_inc. | $25.01 | 2025 | Panhematin |
| Shionogi INC | $24.41 | 2019 | |
| Daiichi Sankyo INC. | $23.72 | 2020 | |
| Tersera Therapeutics LLC | $19.42 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.13 | 2019 | |
| Mallinckrodt Hospital Products INC. | $13.86 | 2023 | Terlivaz |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,800.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Butani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.